新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Celgene出价一亿美元收购Acetylon

Celgene出价一亿美元收购Acetylon

来源:生物谷 2013-07-30 22:24

2013年7月30日讯 /生物谷BIOON/ --Celgene公司一向由于其大胆的收购计划而闻名。此次,Celgene公司又开价一亿美元收购位于波士顿的Acetylon医药公司。Acetylon公司公司目前有一项治疗多发性骨髓瘤的药物正在进行一期临床实验。而这正是Celgene的主要经营领域。

Celgene一直将主要精力放在骨髓瘤治疗领域,并提供了Revlimid、Thalomid和最近刚刚被批准的Pomalyst等药物。此次收购地提出无疑是想要加强公司在该领域的优势。(生物谷Bioon.com)

详细英文报道:

Known for its audacious deals with biotech startups, Celgene ($CELG) forked over $100 million to gain an exclusive option to buy Acetylon Pharmaceuticals. Boston-based Acetylon's most advanced drug candidate is in a Phase Ib clinical trial for multiple myeloma, a blood cancer of strategic importance to Celgene.

Celgene is one of the world's top providers of drugs for myeloma, including Revlimid, Thalomid and its most recently approved therapy Pomalyst. Preclinical research has shown that Acetylon's lead drug, an HDAC6 blocker called ACY-1215, works synergistically with Revlimid, Pomalyst and a range of proteasome inhibitors, company CEO Walter Ogier said in an interview.

"Clearly everyone would like to enhance the effectiveness of their regimens in myeloma and other diseases … [and] do that in a way that doesn't add toxicity to the regimen," Ogier told FierceBiotech.

Summit, NJ-based Celgene, which initially invested $15 million in Acetylon early last year, has agreed to terms that could lead to a buyout of the startup worth $1.7 billion. If Celgene decides to pull the trigger on a buyout of Acetylon, the company must pay up at least $500 million in cash on top of the upfront option fee of $100 million. It would then pay Acetylon shareholders up to $250 million in regulatory milestones and up to $850 million based on sales of drugs from the startup.

Still, Celgene has no obligation to acquire Acetylon, and Ogier declined to reveal the amount of time that the buyout option remains in force. Such option deals are often great on the front end, as shown with the $100 million in non-dilutive cash Acetylon is getting from Celgene, but companies that accept such payments must live with the risks of the option holder declining to buy them or renegotiating for a lower purchase price.

"I think there's a little bit of downside risk if the big company doesn't exercise the option," Ogier said. "And there's always reconsideration for what the purchase price would be. If you negotiate these arrangements correctly, you can minimize those risks."

For instance, Acetylon has garnered a significant upfront option fee, and Ogier expects that the $100 million should enable the company to advance multiple programs to midstage clinical development, potentially making the company far more valuable if those studies pan out well. Acetylon is also able to advance its programs without further dilution to its investors, which consist mostly of wealthy individuals such as the Kraft family that owns the New England Patriots of the NFL. Acetylon has raised $50 million from the sale of equity to those backers and Celgene.

Celgene has barely flinched at hefty sums to acquire early-stage biotech companies. Last year the company scooped up Avila Therapeutics, which was in early clinical trials for a BTK inhibitor, for $350 million upfront and up to $575 million in future payments.

As Ogier says, his investors lacked interest in shooting for an IPO, a tangible option for many biotech companies with targeted cancer drugs like Acetylon. Others such as Epizyme ($EPZM) and Agios Pharmaceuticals ($AGIO) have pulled off two of the most successful public debuts this year, during which more than two dozen drug developers have gone public. The investors, many of which view Acetylon as a philanthropic investment, want to see its drugs get to patients. Acetylon has raised $50 million from the sale of equity to those backers and Celgene.

Celgene has the money and experience to take ACY-1215 all the way, but it's up to the biotech giant to decide whether it wants take full ownership of Acetylon.

 

本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库